Physician profile
Christopher F Schultz
NPI 1497787402
$2,481.42
in general payments reported to CMS, 2019-2025
29 companies · $43.23 in 2025
The $43.23 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $279 · 2021: $438 · 2022: $589 · 2023: $355 · 2024: $238 · 2025: $43.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.29 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.66 | 2019-2024 | Skyrizi, Viberzi, Linzess |
| Janssen Biotech, INC. | $290.98 | 2019-2023 | Stelara |
| Pfizer INC. | $166.72 | 2019-2024 | |
| Gilead Sciences, INC. | $158.07 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.36 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $70.98 | 2021-2025 | Euflexxa |
| Biofire Diagnostics, LLC | $68.05 | 2019 | |
| Celgene Corporation | $60.74 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $58.33 | 2019-2024 | Entyvio |
| Qol Medical, LLC | $45.01 | 2021-2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $43.28 | 2020-2022 | |
| Genzyme Corporation | $34.32 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $33.42 | 2022-2023 | Dupixent |
| Daiichi Sankyo INC. | $33.08 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $29.65 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $26.50 | 2020-2021 | |
| Alfasigma USA, INC. | $24.43 | 2020 | |
| Mallinckrodt Hospital Products INC. | $20.03 | 2020 | |
| Echosens North America, INC. | $20.01 | 2019 | |
| Fresenius Kabi USA, LLC | $18.16 | 2023 | Idacio |
| Ardelyx, INC. | $18.06 | 2022 | |
| Redhill Biopharma INC. | $17.96 | 2020 | |
| Celltrion USA INC. | $14.52 | 2023 | Yuflyma |
| Boston Scientific Corporation | $13.62 | 2023 | Captivator II |
| Ucb, INC. | $12.95 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.68 | 2021 | |
| Allergan, INC. | $12.57 | 2019 | |
| Braintree Laboratories, INC. | $11.81 | 2020 | |
| Intra-Sana Laboratories | $7.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.